Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Clinical Trial to Investigate the Safety, Immunogenicity and Efficacy of BVAC-E6E7 in Subjects With HPV Type 16 and/or 18 Positive Unresectable Recurrent or Metastatic Head

NCT06797986 is registered in ClinicalTrials.gov with Cellid Co., Ltd. as lead sponsor.

NCT NCT06797986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06797986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Clinical Trial to Investigate the Safety, Immunogenicity and Efficacy of BVAC-E6E7 in Subjects With HPV Type 16 and/or 18 Positive Unresectable Recurrent or Metastatic Head
Lead sponsor
Cellid Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 4, 2026
Completion date
March 31, 2027
Enrollment
37 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma (hnscc), hpv (human papillomavirus)-associated carcinoma, hpv positive oropharyngeal squamous cell carcinoma